[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343993-105":59,"doc-detail-343993-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","preclinical-evaluation-of-azd6422-an-armored-chimeric-antigen-receptor-t-cell-targeting-cldn182-in-gastric-pancreatic-and-esophageal-cancers","Preclinical Evaluation of AZD6422 - an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers","","Claudin 18.2 (CLDN18.2) is a surface membrane protein central to tight junctions and highly expressed in gastric, esophageal, and pancreatic cancers, making it a promising target for chimeric antigen receptor T (CAR-T) therapy. Preclinical work addresses the immunosuppressive solid-tumor microenvironment, where TGFβ promotes suppression. AZD6422 combines CAR-T targeting with TGFβ armoring to enhance activity. Lead product design includes CD28/CD3z signaling with dominant-negative TGFβ receptor armoring, and a shortened manufacturing workflow. AZD6422 shows strong antitumor activity and tolerability across patient-derived xenografts, with improved persistence and cytolytic function, supporting further clinical development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-evaluation-of-azd6422-an-armored-chimeric-antigen-receptor-t-cell-targeting-cldn182-in-gastric-pancreatic-and-esophageal-cancers/343993/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-evaluation-of-azd6422-an-armored-chimeric-antigen-receptor-t-cell-targeting-cldn182-in-gastric-pancreatic-and-esophageal-cancers/343993.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CLDN18.2 considered a target for CAR-T therapy in these cancers?","Question",{"text":112,"@type":113},"CLDN18.2 is a surface membrane protein critical for tight junctions and is highly expressed in gastric, esophageal, and pancreatic cancers, supporting CAR-T targeting in these indications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the main challenge for CAR-T therapy in solid tumors addressed by AZD6422?",{"text":117,"@type":113},"Solid tumors often have an immunosuppressive microenvironment, including high TGFβ levels that can inhibit CAR-T function. AZD6422 uses TGFβ armoring to counteract this suppression.",{"name":119,"@type":110,"acceptedAnswer":120},"What preclinical evidence supports AZD6422’s potential?",{"text":121,"@type":113},"AZD6422 demonstrates significant antitumor activity and tolerability in patient-derived xenograft models, increased efficacy in elevated TGFβ settings, and greater persistence and cytolytic function versus traditionally manufactured CAR-T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343993,1790195155,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers  \nAllison M. Barrett1, Zachary T. Britton2, Rosa A. Carrasco1, Shannon Breen1, Maria A.S. Broggi3, Amanda L. Hatke2, Benjamin Clark2, Chunning Yang2, Sandrina Phipps2, Lorenzo Ortiz1, Brianna Janocha1, Peter Zanvit1, Nicolas A. Giraldo4, Philip L. Martin3, Jean-Martin Lapointe5, Nathalie Harder6, Georgina H. Cornish5, Bala N. N. R. Attili5, Yariv Mazor2, Melissa Damschroder2, Mark Cobbold1, Gordon Moody1, and Emily E. Bosco1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Claudin 18.2 (CLDN18.2) is a surface membrane protein that is crucial for maintaining tight junctions in gastric mucosal cells and is highly expressed in gastric, esophageal, and pancreatic cancers. Thus, CLDN18.2 is suited for exploration as a clinical target for chimeric antigen receptor T-cell (CAR-T) therapy in these indications. Although CAR-T therapies show promise, a challenge faced in their development for solid tumors is the immunosuppressive tumor microenvironment, which is often characterized by the presence of immune and stromal cells secreting high levels of TGFβ . The addition of TGFβ armoring can potentially expand CAR-T activity in solid tumors. We report on the preclinical development of a CLDN18.2-targeting CAR-T therapy showing effectiveness in patient models with CLDN18.2-positive gastric, esophageal, and pancreatic tumors.\u003Cbr>Experimental Design: The lead lentivirus product contains a unique single-chain variable fragment; CD28 and CD3z costimulatory\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | and signaling domains; and dominant-negative TGF-β receptor armoring, enhancing targeting and safety and counteracting suppression. We developed a shortened cell manufacturing process to enhance the potency of the final product AZD6422 .\u003Cbr>Results: AZD6422 exhibited significant antitumor activity and tolerability in multiple patient-derived tumor xenograft models with various CLDN18.2 and TGF-β levels, as determined by IHC. The efficacy of armored CAR-T cells in tumor models with elevated TGFβ was increased in vitro and in vivo. In vitro restimulation assays established greater persistence and cytolytic function of AZD6422 compared with a traditionally manufactured CAR-T.\u003Cbr>Conclusions: AZD6422 was safe and efficacious in patientderived, CLDN18.2-positive murine models of gastrointestinal cancers. Our data support further clinical development of AZD6422 for patients with these cancers. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nGastrointestinal (GI) tract cancers, including those of the stomach, esophagus, and pancreas, account for approximately one quarter of cancer incidence and close to one-third of cancer-related mortality worldwide (1, 2). Many factors account for this high mortality, including diagnosis at an ad","cbCaipLICdaANWjB","https://ap.wps.com/l/cbCaipLICdaANWjB","pdf",34894134,17,"English","# Introduction\n# Purpose\n# Experimental Design\n# Results\n# Conclusions","[{\"question\":\"Why is CLDN18.2 considered a target for CAR-T therapy in these cancers?\",\"answer\":\"CLDN18.2 is a surface membrane protein critical for tight junctions and is highly expressed in gastric, esophageal, and pancreatic cancers, supporting CAR-T targeting in these indications.\"},{\"question\":\"What is the main challenge for CAR-T therapy in solid tumors addressed by AZD6422?\",\"answer\":\"Solid tumors often have an immunosuppressive microenvironment, including high TGFβ levels that can inhibit CAR-T function. AZD6422 uses TGFβ armoring to counteract this suppression.\"},{\"question\":\"What preclinical evidence supports AZD6422’s potential?\",\"answer\":\"AZD6422 demonstrates significant antitumor activity and tolerability in patient-derived xenograft models, increased efficacy in elevated TGFβ settings, and greater persistence and cytolytic function versus traditionally manufactured CAR-T cells.\"}]","Preclinical Evaluation of AZD6422 - an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers | PDF",1790052723,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b4e3116cc055ac981a6fffbcb92e507.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3be4723c06e8551d01b4cfdfd34d59c.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d5fe6a16feb39dcb5dd265ddc847648.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98ed1f5cdbd6cafc938cd2daac356468.webp",980,1311]